U.S. pharmaceutical giant Bristol Myers Squibb (BMS) announced Monday its new flagship drug will launch at the same price overseas in the UK as in the U.S., a precedent-breaking move reflecting President Donald Trump’s push to end higher drug costs for Americans.

BMS will launch schizophrenia drug Cobenfy (xanomeline and trospium chloride) in the United Kingdom in 2026 at a list price equal to that in the U.S. The move makes BMS the first to align U.S. and overseas pricing in a huge victory for Trump that validates his push to force change in the industry to end “foreign free-riding.”

“We agree with the Trump Administration that other countries need to pay their fair share,” said Adam Lenkowsky, Chief Commercialization Officer, Bristol Myers Squibb. “By making this commitment, we are ask

See Full Page